Daisuke Shintani

Daisuke Shintani

Auto-generated profile, based on publicly available information

Daisuke Shintani

Department of Gynecology Oncology, Saitama Medical University International Medical Center, Hidaka, Japan

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
PDF file
DSDaisuke Shintani
Daisuke Shintani
THTaro Hihara
Taro Hihara
AOAiko Ogasawara
Aiko Ogasawara
SSSho Sato
Sho Sato
AYAkira Yabuno
Akira Yabuno
KHKosei Hasegawa
Kosei Hasegawa
Objectives Circulating tumor DNA (ctDNA) has potential as a basis for understanding the molecular features of a tumor non-invasively and for use as a diagnostic, prognostic, and disease-monitoring marker. The aim of this study was to evaluate the clinical roles of ctDNA in patients with endometrial cancer. Methods Since PIK3CA and KRAS are among the most common mutated genes in endometrial cancer, somatic mutations of these genes were investigated in tumor specimens and plasma collected before surgery, using droplet digital polymerase chain reaction (ddPCR). ctDNA was defined as positive when the corresponding mutation between somatic and plasma was also detected in plasma cell-free DNA (cfDNA). Relationships of the presence of ctDNA with clinicopathological features were examined. Results Somatic PIK3CA and/or KRAS mutations were found in 68 (34%) of 199 patients with endometrial cancer. Ten (14.7%) of 68 patients had similar mutations in cfDNA. ctDNA detected in pre-operative plasma was correlated with the International Federation of Gynecology and Obstetrics (FIGO) stage (p=0.008), histology (p=0.028), and lymphovascular space invasion (p=0.002), and with shorter recurrence-free and overall survival (p=0.004 and p=0.010, respectively, by log-rank test). Conclusion Tumor-related ctDNA detected in plasma before surgery was associated with poorer oncologic outcome on univariate analysis in patients with endometrial cancer harboring PIK3CA or KRAS mutations.

28 March 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
SYShigehiro Yagishita
Shigehiro Yagishita
TNTadaaki Nishikawa
Tadaaki Nishikawa
HYHiroshi Yoshida
Hiroshi Yoshida
DSDaisuke Shintani
Daisuke Shintani
SSSho Sato
Sho Sato
AHAkinobu Hamada
Akinobu Hamada
Purpose: Uterine carcinosarcoma (UCS), a subtype of endometrial carcinoma, is a rare and aggressive cancer with a poor prognosis. High clinical efficacy of trastuzumab deruxtecan (T-DXd) in HER2-expressing UCS was recently reported in a phase II trial (STATICE trial). We performed a co-clinical study of T-DXd using patient-derived xenograft (PDX) models of participants in the STATICE trial. Experimental Design: Tumor specimens were resected during primary surgery or biopsied at recurrence from patients with UCS and transplanted into immunodeficient mice. Seven UCS-PDXs from six patients were established and HER2, estrogen receptor (ER), and p53 expression in PDX and the original tumor was assessed. Drug efficacy tests were performed using six of the seven PDXs. Of the six UCS-PDXs tested, two were derived from patients enrolled in the STATICE trial. Results: The histopathological characteristics of the six PDXs were well-conserved from the original tumors. HER2 expression was 1+ in all PDXs, and ER and p53 expression was almost similar to that in the original tumors. Remarkable tumor shrinkage after T-DXd administration was observed in four of the six PDXs (67%), comparable with the response rate (70%) of HER2 1+ patients in the STATICE trial. Two patients enrolled in the STATICE trial showed partial response as the best response, and the clinical effect was well-replicated with marked tumor shrinkage. Conclusions: We successfully performed a co-clinical study of T-DXd in HER2-expressing UCS, along with the STATICE trial. Our PDX models can predict clinical efficacy and serve as an effective preclinical evaluation platform.

1 January 2020 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
YIYuji Ikeda
Yuji Ikeda
SSSho Sato
Sho Sato
AYAkira Yabuno
Akira Yabuno
DSDaisuke Shintani
Daisuke Shintani
AOAiko Ogasawara
Aiko Ogasawara
KHKosei Hasegawa
Kosei Hasegawa
Ikeda Y, et al. J Gynecol Oncol. 2019 Jun;31:e93. https://doi.org/10.3802/jgo.2020.31.e93

1 January 2025 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
MOMika Okazawa-Sakai
Mika Okazawa-Sakai
SSShunsuke A. Sakai
Shunsuke A. Sakai
IHIchinosuke Hyodo
Ichinosuke Hyodo
SHSatoshi Horasawa
Satoshi Horasawa
KSKentaro Sawada
Kentaro Sawada
DADaisuke Aoki
Daisuke Aoki
Okazawa-Sakai M, et al. J Gynecol Oncol. 2024 Oct;36:e38. https://doi.org/10.3802/jgo.2025.36.e38

29 April 2020 in In Vivo
Verified
Journal Article
Open access
PDF file
DSDaisuke Shintani
Daisuke Shintani
HYHiroyuki Yoshida
Hiroyuki Yoshida
AYAkira Yabuno
Akira Yabuno
KFKeiichi Fujiwara
Keiichi Fujiwara
Background/Aim: The aim of this study was to compare the tolerability and efficacy of bevacizumab monotherapy between older and younger patients with recurrent ovarian cancer. Patients and Methods: We enrolled 32 patients with recurrent ovarian cancer who were treated with bevacizumab monotherapy and divided them into those who were 65 years and older (n=12) and those younger than 65 years (n=20). Results: Except for grade ≥3 proteinuria, incidences of adverse events did not differ significantly between the groups. Although older patients exhibited more frequently cycle delay caused by non-hematological toxicities, this difference was not significant. There was no significant difference in tumor response and survival between the groups. Conclusion: Bevacizumab monotherapy was tolerable and effective for older patients with recurrent ovarian cancer compared with younger patients.

8 April 2025 in Neoplasia
Verified
Journal Article
Open access
SSSho Sato
Sho Sato
SYShigehiro Yagishita
Shigehiro Yagishita
HYHiroshi Yoshida
Hiroshi Yoshida
DSDaisuke Shintani
Daisuke Shintani
AOAiko Ogasawara
Aiko Ogasawara
KHKosei Hasegawa
Kosei Hasegawa
High-grade endometrial cancer (EC) has a poor prognosis, but molecular classification-based treatments present new therapeutic opportunities. Antibody-drug conjugates (ADC) emerge as promising tools, yet a deeper understanding of antigen dynamics, optimal therapeutic sequencing, and resistance mechanisms is essential. This study investigates the utility of patient-derived xenograft (PDX) models for EC as preclinical platforms, evaluating molecular subtypes and the ADC targets expression of patient and PDX tumors. We developed a comprehensive panel of molecularly characterized PDX models from patients with EC representing various histological types. Molecular subtypes and gene alterations were analyzed using sequencing and immunohistochemistry. ADC targets, including human epidermal growth factor receptor 2, trophoblast cell-surface antigen 2, B7-H4, folate receptor alpha, and cadherin-6, were profiled. Thirty-one EC-PDX models were successfully established, maintaining histological fidelity and 93.1 % molecular subtype consistency with the patient tumors. Notably, 80.6 % of the PDX models exhibited high expression (2+/3+) of at least one ADC target, and 54.8 % displayed high expression of multiple targets. Remarkably, 9.7 % showed high expression of all targets, with gene mutations also characterized. Meanwhile, patient tumors, 78.8 % showed high expression (2+/3+) of at least one ADC target, and 63.6 % showed high expression of multiple targets. The molecularly classified EC-PDX panel, enriched with detailed antigen profiles and genetic data, provides a robust platform for investigating novel ADC therapies and precision treatment strategies for high-grade EC.